middle.news
Invion Advances Photosoft Technology with FDA Designation and Global License
5:52pm on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Invion Advances Photosoft Technology with FDA Designation and Global License
5:52pm on Wednesday 26th of August, 2026 AEST
Key Points
36% reduction in net loss to $5.63 million
Secured expanded perpetual global license for PhotosoftTM
FDA orphan drug designation granted for INV043
Non-dilutive $2 million South Korean government grant
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE